

- 1.1.5. An addition was required to item 4, to add that the NC3Rs meeting will be taking place in London and will focus on cardiovascular research.

2. Matters arising

2.1. Status of applications considered at 14th December 2017

- 2.1.1. [REDACTED], [REDACTED], Regulation of glomerular barrier function in health and disease.

To report: The revised application has been approved by the required Named Persons and Chair of AWERB, and has been signed by the Establishment Licence Holder.

- 2.2. [REDACTED] provided format slides to [REDACTED] to base her presentation on and these will be circulated to the AWERB members.
- 2.3. The Home Office are visiting the BSF on Monday and [REDACTED] will discuss the new AWERB1 form and circulation of the PPLs for members to review.

3. NW region AWERB hub

- 3.1. The next meeting will be held in Manchester in June 2018 (a specific date to be determined)
- 3.2. The Chair will be attending the AWERB Chairs meeting in London on 6th March 2018 and invites members of AWERB to also attend. The Chair will report back to AWERB after the meeting.

4. Report from the NC3Rs Regional Programme Manager

- 4.1. There will be an NC3Rs Summer School taking place in either Manchester or Liverpool, with the location being decided in the next few weeks. The Summer School has limited places and is open to 1st year PhD students who have NC3Rs funding. 4-5 students who are not funded by the NC3Rs will be invited to attend the Summer School. An open call will go out, with interested students asked to complete an application form. [REDACTED] would like members of AWERB to help with shortlisting the applications to choose who will attend. The Summer School aims to promote 3Rs initiatives and give skills to students who attend.
- 4.2. [REDACTED] is organising targeted workshops and would welcome ideas from members on topics which could be covered. Currently the topics include the use of analgesia and non-mammalian models.

- 4.3. [REDACTED] would like to find ways to support postgraduate students, and while bioethics is currently covered, [REDACTED] would ideally like a module to cover the 3Rs.

5. Licences processed from 04/12/2018 – 30/01/2018

5.1. Amendments to Project Licences

- 5.1.1. [REDACTED], 'Cancer Biology Including Host Immunity in Zebrafish'.

To report: The amendment has been approved by the executive committee.

- 5.1.2. [REDACTED], 'The Role of Inflammation in Cerebrovascular Disease'.

To report: The amendment has been approved by the executive committee.

- 5.1.3. [REDACTED], 'Engineering Synthetic Vectors for Various Gene Therapy Applications'.

To report: The amendment has been approved by the executive committee.

- 5.1.4. [REDACTED], 'Preclinical Evaluation of Cancer Therapeutics (Change of PPL Holder)'.

To report: The amendment has been approved by the executive committee.

5.2. Amendments to Project Licence [REDACTED]; Generation, Breeding and Maintenance of Genetically Altered Rodents

- 5.2.1. [REDACTED].

5.3. Amendments to Project Licence [REDACTED], Breeding and Maintenance of Genetically Altered Rodents

None

5.4. Amendments to Project Licence [REDACTED], Generation & Breeding of Genetically Altered Rodents

None

5.5. Applications for New Project Licences

- 5.5.1. [REDACTED] Drug Discovery for Parasitic Helminths ([REDACTED])

Considered: AWERB1 form version 2017-2 and PPL form

Interviewed: ██████████

Discussed:

1. The Committee discussed with the applicant if there were sufficient numbers to confirm efficacy in Protocol 1. ██████████ outlined a previous study but stated that since no in vivo work has been done as yet the sample size is difficult to know.
2. The Committee asked the applicant why the pharmacokinetic study was not being combined with the tolerability study. The applicant explained that metabolic changes to the mouse after the introduction of the worm would lead to noise within the pharmacokinetic data; therefore the decision was made to keep the tolerability and pharmacokinetic studies separate.
3. The Committee asked about the planned doses to be given to the animals based on the fact that the stated doses would not clear the worms in humans. ██████████ explained that other factors may affect how drugs work within man, and the doses in the application are based on previous studies that have been shown to clear the mouse of the worm.
4. Given the use of inbred mice the Committee asked how this would relate to the real world. ██████████ explained that the planned research is a good starting point before studies are designed to take into consideration how the research would be translated to humans.
5. The Committee asked for some clarity between the mild and moderate diarrhoea humane end points. The Committee advise ██████████ to meet with the NC3Rs Regional Programme Manager and NVS to discuss this issue.
6. The Committee felt that the NTS would be enhanced by some redrafting and a potential reduction in size. Given the NTS is produced for lay members, ██████████ and ██████████ would be available for advice on how to go about this. The Committee felt that the term “humanely killed” should be used within the NTS.
7. The Committee advise ██████████ to update the application based on discussions with the Named Persons during the pre-AWERB meeting.
8. The Committee would like the application to include numbers in addition to the phrases “rarely” and “occasionally” to provide clarity on how often the expected frequency of adverse effects are expected, whilst understanding that the Home Office require the use of these terms.
9. The applicant was asked to check the Body Condition Scores, as the Committee were unsure if the <2 for the last expected adverse effect in Table 6 was meant to be <3.
10. Item (b) for the protocol steps in Protocol 1 states gavage no more than 2x daily for 5 days, however the maximum number of doses is listed as 14. Please can the applicant clarify this.

Outcome: The study has provisional approval based on the applicant making the changes/clarifications listed above to the satisfaction of the Chair/AWERB.

5.6. Applications for Cat D work

None

5.7. Applications for secondary availability for new or current project licences

None

5.8. Application for secondary availability for imaging purposes

None

5.9. Project Licences for review

None

6. Any other business

6.1. Presentation from [REDACTED]

[REDACTED] gave the presentation that she had given at the RSPCA AWERB Lay Members Forum in December which showed what worked for the AWERB based in CRUK MI.

6.2. Report from RSPCA AWERB Lay Members' Forum Dec 17

[REDACTED] and [REDACTED] summarised the presentations from the RSPCA AWERB Lay Members Forum which they both felt was very informative. The full presentations have been previously circulated to AWERB members.

6.3. AWERB processes

6.3.1. Given the large number of members on AWERB, the Chair raised the suggestion that members do not attend all meetings, although they are more than welcome to. Once the dates of the 2018/2019 meetings are arranged they will be circulated and members will be asked to sign-up to those that they plan to attend.

- 6.3.2. Future applications should be accompanied by both the notes from the pre-AWERB meeting and the notes from discussions between Inferstats and the applicant so that the AWERB members are aware of previous discussions that have taken place regarding the application.
- 6.3.3. Guidelines for the NTS and a glossary of terms were proposed, with [REDACTED] taking the lead on this. The draft guidelines and glossary will be circulated prior to the next meeting for consideration when the Committee meet. Once approved, the guidelines will be made available to Project Licence applicants.
- 6.4. [REDACTED] has received the IAT Editorial Board 2017 Majorie Sandiford Journal Article prize for her paper "*Do Buccal swabs from Zebrafish give enough of a sample of DNA to be used as a viable non-invasive method of genotyping?*". The Committee send their congratulations to [REDACTED] who will be attending a meeting in Harrogate where she will receive her prize.
- 6.5. Under [REDACTED] advice, the technicians in the BSF are trialling a technique for handling animals which involves the use of tubes. During training the technician time will be increased, but this was felt to be in line with any new technique being introduced or the training of a new member of technical staff.
- 6.6. [REDACTED] outlined that the NC3Rs are running a course for technicians as part of the next IAT congress.